Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02143986 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Glycosylated Ferritin in Macrophagic Activation Syndromes

Study acronym: FERRITGLY01
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Notable Primary and study completion dates: Dec 2020 to Dec 2030v7
  2. Minor Re-verified, no change to tracked fieldsv6
  3. Notable Primary and study completion dates: Dec 2018 to Dec 2020v5
  4. Notable Primary and study completion dates: Dec 2017 to Dec 2018v4
  5. Notable Primary and study completion dates: Dec 2016 to Dec 2017v3
  6. Notable Primary completion date: Jul 2015 to Dec 2016
    • Study completion date: Jul 2016 to Dec 2016
    v2
  7. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In healthy subjects, from 50 to 80 % of the serum ferritin is glycosylated \[1, 2\] . A decrease in the percentage of ferritin glycosylation can be observed in inflammatory diseases, malignancies, infections, or liver disease but is rarely less than 20% \[3 , 4\] . Percentage of glycosylated ferritin below 20% have been described in patients with adult Still's disease and haemophagocytosis lymphohistiocytic syndromes (HLH). The glycosylated ferritin has been included in the diagnostic criteria for Still's disease in adults. A cut-off of less than 20 % has a sensitivity and specificity of 72 and 69 % respectively , and 35 and 94 % when combined with a total ferritin level greater than 5 times normal value. This parameter was also suggested to be a more specific marker to confirm a diagnosis of HLH than a high ferritin level ( \> 500μg / L). However, several limitations of this parameter were highlighted, some conditions making its interpretation difficult : particularly in cases of major hepatic cytolysis and severe sepsis (miliary tuberculosis, lymphoma and disease Adult Still). It is not always possible to distinguish severe sepsis, HLH syndrome and Still's disease. A fine analysis of various glycoforms components of ferritin could be used to distinguish different subgroups of patients. Few data are available on the mechanism of secretion and glycosylation of ferritin, but the investigators assume that the glycosylation patterns of ferritin may vary between different disease states and reflect distinct underlying pathophysiological mechanisms.
Trial Details
NCT Number NCT02143986
Lead Sponsor Brugmann University Hospital
Collaborators: Université Libre de Bruxelles
Conditions
(from sponsor)
Still's Disease, Adult-Onset, Sepsis, Macrophagic Activation Syndrome
Related terms Arthritis, Juvenile, Sepsis, Still's Disease, Adult-Onset
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov